Skin Deep: The Intersection of Pityriasis Versicolor and Systemic Lupus Erythematosus

Marsa Zaidan, Triasari Oktavriana

Abstract

Pityriasis versicolor, a superficial fungal infection caused by Malassezia. Diagnosis typically relies on clinical appearance and laboratory tests, including microscopic examination and wood lamp examination. This study presents a case of a 27-year-old woman with systemic lupus erythematosus (SLE) who developed pityriasis versicolor characterized by hypopigmented patches and itching exacerbated by heat and sweating. The results of clinical and supporting examinations, this patient was given therapy with itraconazole. The findings highlight the increased susceptibility of SLE patients to skin infections due to immunosuppressive therapies and the importance of recognizing pityriasis versicolor as a potential complication in this demographic. The study emphasizes that while both immunocompetent and immunocompromised individuals exhibit similar characteristics of pityriasis versicolor, the latter group is at a higher risk for severe infections. Effective management strategies include both topical and systemic antifungal treatments tailored to the severity of the condition while considering the underlying immunosuppressive status.

Keywords: pityriasis versicolor; clinical manifestation, systemic lupus erythematosus, management

References

Merad Y, Merad S, Belkacemi M, Belmokhtar Z. Extensive P ityriasis Versicolor Lesions in an Immunocompetent Parking Attendant : An Occupational Disorder ? 2022;(August).

Smith MA, Henault J, Karnell JL, Parker ML, Riggs JM, Sinibaldi D, et al. SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus. Sci Rep. 2019;9(1):1–12.

Haider MZ, Islam N, Asaduzzaman ATM, Shoaib M, Majumder M, Shazzad N, et al. Risk Factors for Skin Infection in Patients with Systemic Lupus Erythematosus Annals of International Medical and Dental Research. 2023;4(4):73–82.

Ramnarain A, Liam C, Milea D, Morand E, Kent J, Kandane-Rathnayake R. Predictors of Organ Damage in Systemic Lupus Erythematosus in the Asia Pacific Region: A Systematic Review. Arthritis Care Res. 2024;76(5):720–32.

Kang S, Amagai M, Bruckner AL, M AHE, Margolis DJ, Orringer JS, et al. Fitzpatrick’s Dermatology 9th edition. 9th ed. Hill MG, editor. 2019. 4120 p.

Hikmah Z, Endaryanto A, Gede Ugrasena I. Systemic lupus erythematosus organ manifestation and disease activity in children based on Mexican systemic lupus erythematosus disease activity index score at East Java, Indonesia. Indian J Rheumatol. 2021;16(4):408–14.

Kole A, Ghosh A. Cutaneous manifestations of systemic lupus erythematosus in a tertiary referral center. Indian J Dermatol. 2009;54(2):132–6.

Łabędź N, Navarrete-Dechent C, Kubisiak-Rzepczyk H, Bowszyc-Dmochowska M, Pogorzelska-Antkowiak A, Pietkiewicz P. Pityriasis Versicolor—A Narrative Review on the Diagnosis and Management. Life. 2023;13(10).

Fanouriakis A, Bertsias G, Boumpas DT. Hydroxychloroquine dosing in systemic lupus erythematosus: Response to € Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al’ by Costedoat-Chalumeau et al. Ann Rheum Dis. 2020;79(8):2020.

Zhou P, Chen J, He J, Zheng T, Yunis J, Makota V, et al. Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus. PLoS Pathog [Internet]. 2021;17(10):1–25. Available from: http://dx.doi.org/10.1371/journal.ppat.1009858

He J, Li Z. Dilemma of immunosuppression and infection risk in systemic lupus erythematosus. Rheumatol (United Kingdom). 2023;62:I22–9.

Liao W, Lin JX, Leonard WJ. Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy. Immunity [Internet]. 2013;38(1):13–25. Available from: http://dx.doi.org/10.1016/j.immuni.2013.01.004

Leung AK, Barankin B, Lam JM, Leong KF, Hon KL. Tinea versicolor: an updated review. Nurse Pract. 2022;11(2):30–5.

DOI: https://doi.org/10.20961/mshmj.v3i1.97697

Refbacks

  • There are currently no refbacks.